BHC Earnings Day: The $4.68 Stock With a $7.30 Analyst Target

Bausch Health Companies enters its Q2 print today with the stock up 3.5% on the session to $4.68 — still trading at a steep discount to the Street's mean target of $7.30, a gap that has persisted all month and frames the central question heading into the release.

The positioning setup remains notably relaxed despite a month of steady short accumulation. Short interest has climbed 22% over the past 30 days to roughly 2.1% of the free float — low in absolute terms, and the lending market confirms there is no stress behind it. Availability runs above 1,000%, meaning around ten shares remain available to borrow for every one already lent out. Borrowing costs have ticked up 71% on the week to 0.57% but remain trivially cheap. The options market has actually become slightly less defensive into the print: the put/call ratio eased to 1.54, just below its 20-day average of 1.61. None of these signals point to a charged or crowded setup — short sellers have been building slowly, not urgently.

The bull-bear divide is structural rather than tactical. Bulls point to Solta Medical's 28% year-over-year growth and Ryaltris-driven strength in Canada, where revenues rose 9%, as evidence that the company's diversified model has genuinely improving pockets. Analysts broadly maintain hold-equivalent ratings — RBC at Sector Perform, Barclays at Equal-Weight — with targets clustered between $7 and $9, well above the current price. Bears focus on the international drag, particularly Latin America's 14% annual decline, and a projected 7% revenue drop by 2027 tied to IRA headwinds. The most recent analyst move of note was RBC trimming its target to $9 in late April. Multiples offer little comfort either way: EV/EBITDA near 6x and a price-to-earnings ratio barely above 1x reflect a market that is not paying for growth.

The two most recent earnings prints produced muted but positive 1-day reactions of roughly 3% and 1.8% respectively, with the five-day window mixed. Today's report will test whether the Solta and Canada growth story is durable enough to close any part of the gap between the stock's $4.68 handle and a Street consensus that, for now, the market has chosen not to believe.